Lymphatic blood filling in CLEC-2-deficient mouse models
Research output: Contribution to journal › Article
- Division of Plastic and Reconstructive Surgery, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.
- Institut National de la Santé et de la Recherche Médicale, UMR_S1148, Université Paris Diderot, Sorbonne Paris Cité, Hôpital Bichat, Paris, France
- Department of Experimental Biomedicine; University Hospital, University of Würzburg; Würzburg Germany
C-type lectin-like receptor 2 (CLEC-2) is considered as a potential drug target in settings of wound healing, inflammation and infection. A potential barrier to this is evidence that CLEC-2, and its ligand podoplanin, play a critical role in preventing lymphatic vessel blood filling in mice throughout life. In this study, this aspect of CLEC-2/podoplanin function is investigated in more detail using new and established mouse models of CLEC-2 and podoplanin deficiency, and models of acute and chronic vascular remodeling. We report that CLEC-2 expression on platelets is not required to maintain a barrier between the blood and lymphatic systems in unchallenged mice, post-development. However, under certain conditions of chronic vascular remodeling, such as during tumorigenesis, deficiency in CLEC-2 can lead to lymphatic vessel blood filling. These data provide new understanding of the function of CLEC-2 in adult mice, and confirms the essential nature of CLEC-2 driven platelet activation in vascular developmental programs. This work expands our understanding of how lymphatic blood filling is prevented by CLEC-2 dependent platelet function, and provides a context for the development of safe targeting strategies for CLEC-2 and podoplanin.
|Early online date||4 Mar 2020|
|Publication status||E-pub ahead of print - 4 Mar 2020|
- Blood-lymphatic separation, CLEC-2, platelets, podoplanin